γδ T cells in cancer
The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
With the promise of T cell-based therapy for cancer finally becoming reality, this Review focuses on the less-studied γδ T cell lineage and its diverse responses to tumours. γδ T cells have well-established protective roles in cancer, largely on the basis of their potent cytotoxicity and interferon-γ production. Besides this, recent studies have revealed a series of tumour-promoting functions that are linked to interleukin-17-producing γδ T cells. Here, we integrate the current knowledge from both human and mouse studies to highlight the potential of γδ T cell modulation to improve cancer immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“γδ T cells can have either protective roles or tumor-promoting functions in cancer; tumor-promoting activities of γδ T cells have been ascribed to distinct mechanisms in different types of cancers (Daley et al., 2016; Silva-Santos et al., 2015).”
From Commensal Microbiota Promote Lung Cancer Development via γδ T Cells (2019) · cites this paper as Silva-Santos et al., 2015
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Immune adaptations that maintain homeostasis with the intestinal microbiota
Hooper, L. V., & Macpherson, A. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2710 · Cited by 1,454
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232
Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Research works printed but not linked: 1
- Gu, S., Nawrocka, W. & Adams, E. J. Sensing of pyrophosphate metabolites by Vγ9Vδ2 T cells. Front. Immunol. 5, 688 (2014).
Cited by
Items 201–300 of 593
Presti, E. L., Mocciaro, F., Mitri, R. D., Corsale, A. M., Simone, M. D., Vieni, S., Scibetta, N., Unti, E., Dieli, F., & Meraviglia, S. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ma0320-201rr · Cited by 35
Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
Cutmore, L. C., & Marshall, J. F. (2021) · Cancers · doi:10.3390/cancers13081926 · Cited by 36
“γδ T cells are a key component of the innate immune system that help to detect and eradicate tumour cells [51].”
BackgroundZhang, Z., Yang, C., Li, L., Zhu, Y., Su, K., Zhai, L., Wang, Z., & Huang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699478 · Cited by 46
Deciphering human γδ T cell response in cancer: Lessons from tumor‐infiltrating γδ T cells
Presti, E. L., Dieli, F., Fournié, J., & Meraviglia, S. (2020) · Immunological Reviews · doi:10.1111/imr.12904 · Cited by 34
Yaddanapudi, K., Stamp, B. F., Subrahmanyam, P. B., Smolenkov, A., Waigel, S. J., Gosain, R., Egger, M. E., Martin, R. C. G., Buscaglia, R., Maecker, H. T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0664 · Cited by 35
Chen, B., Xi, Y., Zhao, J., Hong, Y., Tian, S., Zhai, X., Chen, Q., Ren, X., Fan, L., Xie, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049435 · Cited by 37
Yang, J., Jones, M. S., Ramos, R. I., Chan, A. A., Lee, A. F., Foshag, L. J., Sieling, P. A., Faries, M. B., & Lee, D. J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00061 · Cited by 35
Dysfunctional tumor-infiltrating Vδ1 + T lymphocytes in microsatellite-stable colorectal cancer
Stary, V., Pandey, R. V., List, J., Kleißl, L., Deckert, F., Kabiljo, J., Laengle, J., Gerakopoulos, V., Oehler, R., Watzke, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51025-1 · Cited by 34
Gamma delta T cells and their immunotherapeutic potential in cancer
Cieslak, S. G., & Shahbazi, R. (2025) · Biomarker Research · doi:10.1186/s40364-025-00762-6 · Cited by 38
“Additionally, γδ T cells are fundamentally similar to natural killer (NK) cells in that γδ T cells recognize neoplastic or infected cells through multiple receptor–ligand interactions, quickly responding in an innate-like manner without requiring prior exposure [1, 4, 5].”
Evolving adoptive cellular therapies in urological malignancies
Wong, Y. N. S., Joshi, K., Pulè, M. A., Peggs, K. S., Swanton, C., Quezada, S. A., & Linch, M. D. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30327-3 · Cited by 38
Wu, X., Shi, X., Zhai, K., Yi, F., Wang, Z., Wang, W., Pei, X., Xu, L., Wang, Z., & Shi, H. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00120.2018 · Cited by 39
The next level of 3D tumour models: immunocompetence
Nyga, A., Neves, J. B., Stamati, K., Loizidou, M., Emberton, M., & Cheema, U. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.010 · Cited by 37
γδ T cells and the PD-1/PD-L1 axis: a love–hate relationship in the tumor microenvironment
Liu, J., Wu, M., Yang, Y., Wang, Z., He, S., Tian, X., & Wang, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05327-z · Cited by 34
“These cells have been proven to drive cancer progression by exerting downstream effects on cancer cells, endothelial cells, and other immune cell populations [5].”
BackgroundNew insights into the biology of T-cell lymphomas
Iqbal, J., Inghirami, G. G., & Chan, W. C. (2024) · Blood · doi:10.1182/blood.2023021787 · Cited by 36
Development and Function of γδT Cells in the Oral Mucosa
Hovav, A., Wilharm, A., Barel, O., & Prinz, I. (2020) · Journal of Dental Research · doi:10.1177/0022034520908839 · Cited by 32
Story, J. Y., Zoine, J. T., Burnham, R. E., Hamilton, J. A. G., Spencer, H. T., Doering, C. B., & Raikar, S. S. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.09.010 · Cited by 32
Dichotomous and stable gamma delta T-cell number and function in healthy individuals
Ou, L., Wang, H., Liu, Q., Zhang, J., Lu, H., Luo, L., Shi, C., Lin, S., Dong, L., Guo, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002274 · Cited by 36
Watanabe, D., Koyanagi‐Aoi, M., Taniguchi‐Ikeda, M., Yoshida, Y., Azuma, T., & Aoi, T. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0021 · Cited by 33
γδ T cells: an immunotherapeutic approach for HIV cure strategies
Garrido, C., Clohosey, M. L., Whitworth, C. P., Hudgens, M. G., Margolis, D. M., & Soriano-Sarabia, N. (2018) · JCI Insight · doi:10.1172/jci.insight.120121 · Cited by 33
“Once activated, V δ 2 cells are potent cytotoxic effectors (17) against malignancies (18, 19) and HIV-infected cells (20–23).”
BackgroundEcto-ATPase CD39 Inactivates Isoprenoid-Derived Vγ9Vδ2 T Cell Phosphoantigens
Gruenbacher, G., Gander, H., Rahm, A., Idzko, M., Nussbaumer, O., & Thurnher, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.009 · Cited by 34
“…to perform innate-like responses, Vg9Vd2 T cells express CD161 (KLRB1) and the transcription factors T-bet and eomesodermin (Dimova et al., 2015; Fergusson et al., 2014; Gruenbacher et al., 2014; Ribot et al., 2014). gd T cells have promising anti-tumor potential (Silva-Santos et al., 2015).”
BackgroundCarpen, L., Falvo, P., Orecchioni, S., Mitola, G., Hillje, R., Mazzara, S., Mancuso, P., Pileri, S. A., Raveane, A., & Bertolini, F. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00893-x · Cited by 37
“This might be associated with a recently discovered mouse pro-tumoral activity of these specific cell populations [44, 49], also confirmed by the high expression of Il17a, a marker proved to promote the expansion of pro-tumoral γδ T cells [50].”
BackgroundCAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
Ren, A., Tong, X., Xu, N., Zhang, T., Zhou, F., & Zhu, H. (2023) · Vaccines · doi:10.3390/vaccines11010165 · Cited by 32
Activated Chicken Gamma Delta T Cells Are Involved in Protective Immunity against Marek’s Disease
Matsuyama-Kato, A., Shojadoost, B., Boodhoo, N., Raj, S., Alizadeh, M., Fazel, F., Fletcher, C., Zheng, J., Gupta, B., Abdul-Careem, M. F., et al. (2023) · Viruses · doi:10.3390/v15020285 · Cited by 35
Baird, L., & Yamamoto, M. P. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102904 · Cited by 31
Veluchamy, J. P., Delso-Vallejo, M., Kok, N., Bohme, F., Seggewiß-Bernhardt, R., van der Vliet, H. J., de Gruijl, T. D., Huppert, V., & Spanholtz, J. (2017) · Scientific Reports · doi:10.1038/srep43873 · Cited by 33
Ravens, S., Hengst, J., Schlapphoff, V., Deterding, K., Dhingra, A., Schultze-Florey, C. R., Koenecke, C., Cornberg, M., Wedemeyer, H. H., & Prinz, I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00510 · Cited by 32
“Overall, non-Vγ9JP+Vδ2+ γδ T cells exert a high degree of antiviral and antitumor activity (15, 16), which is for instance reflected in the expansion of Vδ1+ γδ T cells in response to viral infection in immunocompromised patients, stem cell transplant recipients, and during pregnancy (17–21).”
BackgroundIL-17A-producing T cells are associated with the progression of lung adenocarcinoma
Bao, Z., Lu, G., Cui, D., Yao, Y., Yang, G., & Zhou, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4837 · Cited by 30
“γδT17 cells, the primary source of IL-17 in the early stage of some diseases and one of the pivotal players in immune surveillance, display diverse responses to tumors (20,53).”
BackgroundModulation of lytic molecules restrain serial killing in γδ T lymphocytes
Sandoz, P. A., Kuhnigk, K., Szabo, E. K., Thunberg, S., Erikson, E., Sandström, N., Verron, Q., Brech, A., Watzl, C., Wagner, A. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41634-7 · Cited by 31
The current understanding of the immune landscape relative to radiotherapy across tumor types
Iliadi, C., Verset, L., Bouchart, C., Martinive, P., Gestel, D. V., & Krayem, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148692 · Cited by 29
Chang, K., Traum, D., Park, J., Ho, S., Ojiro, K., Wong, D., Wahed, A. S., Terrault, N. A., Khalili, M., Sterling, R. K., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007715 · Cited by 29
Odaira, K., Kimura, S., Fujieda, N., Kobayashi, Y., Kambara, K., Takahashi, T., Izumi, T., Matsushita, H., & Kakimi, K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.115 · Cited by 29
“They are present mainly in the periphery, such as in epithelia and peripheral blood, and participate in the rapid lymphoid stress-surveillance system for mycobacteria, tissue perturbation and transformed cells [2, 3 , 4].”
BackgroundThe Emerging Complexity of γδT17 Cells
McKenzie, D. R., Comerford, I., Silva‐Santos, B., & McColl, S. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00796 · Cited by 29
Self-citationHan, J., Zhang, S., Xu, Y., Pang, Y., Zhang, X., Hu, Y., Chen, H., Chen, W., Zhang, J., & He, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01380 · Cited by 33
“Furthermore, Vδ2Vγ9 T cells possess the characteristics of selfactivation and release the Th1-type cytokine interferon gamma (IFN-γ) and other cytotoxic cytokines, such as tumor necrosis factor (TNF), perforin, and granzymes (granzyme A and B), to eliminate tumor cells (8, 13, 14).”
BackgroundA Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Chiu, D. T.-Y., Qi, J., Thin, T. H., Garcia-Barros, M., Lee, B. H., Hahn, M., Mandeli, J., Belani, P. B., Nael, K., Rashidipour, O., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0420 · Cited by 28
Yu, L., Wang, Z., Hu, Y., Wang, Y., Lü, N., & Zhang, C. (2023) · International Journal of Cancer · doi:10.1002/ijc.34669 · Cited by 29
“γδT-cells are important constituents of the TIL population, and therefore have the potential to improve cancer immunotherapy.(18,30) T-cell exhaustion is a major obstacle to the efficacy of immunotherapy.”
BackgroundYin, W., Tong, S., Zhang, Q., shao, J., Liu, Q., Peng, H., Hu, H., Peng, M., Hu, P., Ren, H., et al. (2016) · Scientific Reports · doi:10.1038/srep26296 · Cited by 28
Overgaard, N. H., Principe, D. R., Schachtschneider, K. M., Jakobsen, J. T., Rund, L. A., Grippo, P. J., Schook, L. B., & Jungersen, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01301 · Cited by 29
“infiltrated by a Distinct subset of γδ T cells While conventional αβ T cells have received a lot of attention, γδ T cells have been much less studied, although they have been demonstrated to have implications in cancer (52).”
BackgroundCapTCR-seq: hybrid capture for T-cell receptor repertoire profiling
Mulder, D. T., Mahé, E., Dowar, M., Hanna, Y., Li, T., Nguyen, L. T., Butler, M. O., Hirano, N., Delabie, J., Ohashi, P. S., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017014639 · Cited by 29
Song, L., Ma, S., Chen, L., Miao, L., Tao, M., & Liu, H. (2019) · Cancer Science · doi:10.1111/cas.14068 · Cited by 30
Ghosh, A., Mondal, R., Romani, S., Bagchi, S., Cairo, C., Pauza, C. D., Kottilil, S., & Poonia, B. (2019) · Journal of Viral Hepatitis · doi:10.1111/jvh.13121 · Cited by 29
Ultrasmall silica nanoparticles directly ligate the T cell receptor complex
Vis, B., Hewitt, R. E., Monie, T. P., Fairbairn, C., Turner, S. D., Kinrade, S. D., & Powell, J. J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911360117 · Cited by 28
The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy
Acker, H. H. V., Campillo-Davó, D., Roex, G., Versteven, M., Smits, E., & Tendeloo, V. F. V. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.05.002 · Cited by 30
Liu, J., Gao, H., Xu, L., Mo, X., Liu, R., Liang, S., Wu, N., Wang, M., Wang, Z., Chang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000208 · Cited by 27
Zhao, B., Wang, Y., Wang, Y., Chen, W., Liu, P. H., Kong, Z., Dai, C., Wang, Y., & Ma, W. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29878 · Cited by 28
Dutta, I., Dieters‐Castator, D. Z., Papatzimas, J. W., Medina, A., Schüler, J. B., Derksen, D. J., Lajoie, G., Postovit, L.-M. M., & Siegers, G. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.013 · Cited by 27
Our evolving understanding of the role of the γδ T cell receptor in γδ T cell mediated immunity
Gully, B. S., Rossjohn, J., & Davey, M. S. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200890 · Cited by 27
Shiah, S., Chou, S.-T., & Chang, J. (2021) · Cancers · doi:10.3390/cancers13225604 · Cited by 28
Liu, M., Liu, Z., Chen, Y., Peng, S., Yang, J., Chen, C., Wang, J., Shang, R., Tang, Y., Huang, Y., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02783-6 · Cited by 28
Not all LGL leukemias are created equal
Semenzato, G., Calabretto, G., Barilà, G., Gasparini, V. R., Teramo, A., & Zambello, R. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101058 · Cited by 26
γδT cells, a key subset of T cell for cancer immunotherapy
Lv, J., Liu, Z., Ren, X., Song, S., Zhang, Y., & Wang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1562188 · Cited by 28
Samy, M. D., Tong, W. L., Yavorski, J. M., Sexton, W. J., & Blanck, G. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1943-1 · Cited by 25
ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells
Riganti, C., Castella, B., & Massaia, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01246 · Cited by 26
“This metabolic derangement leads to increased IPP production which is sensed by Vγ9Vδ2 T cells laying the basis of their multifaceted contribution to immune surveillance and antitumor immunity (4).”
BackgroundJuraske, C., Wipa, P., Morath, A., Hidalgo, J. V., Hartl, F. A., Raute, K., Oberg, H., Wesch, D., Fisch, P., Minguet, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01579 · Cited by 25
“Alternatively, γδ T cells recognize cell surface molecules that are differentially expressed on transformed solid tumors or lymphomas and leukemias (7, 15).”
BackgroundDiminished cytolytic activity of γδ T cells with reduced DNAM-1 expression in neuroblastoma patients
Wang, X., Mou, W., Han, W., Xi, Y., Chen, X., Zhang, H., Qin, H., Wang, H., Ma, X., & Gui, J. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.04.006 · Cited by 25
Zaghi, E., Calvi, M., Vito, C. D., & Mavilio, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02794 · Cited by 25
“In addition to their TCR, γδ T cells express an array of pattern-recognition receptors, such as toll-like receptors (TLRs) (201, 204), activating and inhibitory NKRs (201, 205, 206), the NCRs NKp30 and NKp44 (206, 207), the aNKR DNAM-1, the Fc receptor CD16 as well as the C-type lectin-like receptors NKG2D and CD94/NK…”
BackgroundInfluentialAoki, T., Takami, M., Takatani, T., Motoyoshi, K., Ishii, A., Hara, A., Toyoda, T., Okada, R., Hino, M., Koyama‐Nasu, R., et al. (2020) · Cancer Science · doi:10.1111/cas.14428 · Cited by 26
Early antitumor activity of oral Langerhans cells is compromised by a carcinogen
Saba, Y., Aizenbud, I., Matanes, D., Koren, N., Barel, O., Zubeidat, K., Capucha, T., David, E., Eli‐Berchoer, L., Stoitzner, P., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2118424119 · Cited by 29
The landscape of CAR-engineered innate immune cells for cancer immunotherapy
Tsahouridis, O., Xu, M., Song, F., Savoldo, B., & Dotti, G. (2025) · Nature Cancer · doi:10.1038/s43018-025-01015-z · Cited by 28
“Human γδ T cells can infiltrate tumors, where their presence is associated with positive prognoses in several malignancies 105–107 . γδ T cells display cytotoxic activity against transformed cells 105 , with tumor-derived phosphoantigens inducing the effector function of Vγ9Vδ2 + T cells 108 .”
Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer
Zheng, Y., Wang, P., Fu, Y., Chen, Y.-Y., & Ding, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109030 · Cited by 29
Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells
Boucher, J. C., Yu, B., Li, G., Shrestha, B., Sallman, D. A., Landin, A. M., Cox, C. A., Karyampudi, K., Anasetti, C., Davila, M. L., et al. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000445 · Cited by 24
γδ T cells and their clinical application in colon cancer
Corsale, A. M., Simone, M. D., Presti, E. L., Dieli, F., & Meraviglia, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1098847 · Cited by 26
Moresco, M. A., Raccosta, L., Corna, G., Maggioni, D., Soncini, M., Bicciato, S., Doglioni, C., & Russo, V. E. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02251 · Cited by 24
Pan-cancer γδ TCR analysis uncovers clonotype diversity and prognostic potential
Yu, X., Song, L., Cen, L., Cao, B., Tao, R., Shen, Y., Abate‐Daga, D., Rodríguez, P. C., Conejo-Garcia, J. R., & Wang, X. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101764 · Cited by 28
Dunne, P. D., O’Reilly, P. G., Coleman, H. G., Gray, R. T., Longley, D. B., Johnston, P. G., Salto‐Tellez, M., Lawler, M., & McArt, D. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9126 · Cited by 24
Age dependent differences in the kinetics of γδ T cells after influenza vaccination
Stervbo, U., Pohlmann, D., Baron, U., Bozzetti, C., Jürchott, K., Mälzer, J. N., Nienen, M., Olek, S., Roch, T., Schulz, A. R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181161 · Cited by 26
Zhou, B., Gong, J.-H., Cai, X., Wang, J., Luo, F., Jiang, N., Gong, J., Du, C., & Liao, R. (2019) · Hepatology International · doi:10.1007/s12072-019-09969-w · Cited by 23
Chiu, Y., Wang, L., Lu, T., Hsiao, T.-H., Chuang, E. Y.-Y., & Chen, Y. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1557-4 · Cited by 23
“It was implied to be associated with apoptosis of GBM cells [56] and to participate in IL-15 induced activation of tumor-specific gamma delta T cells [57], a subset of T cells that express a unique T cell receptor and are multi-functional in cancer [58].”
Optical spectroscopic imaging for cell therapy and tissue engineering
Park, G. K., Hoseok, I., Kim, G. S., Hwang, N. S.-Y., & Choi, H. S. (2017) · Applied Spectroscopy Reviews · doi:10.1080/05704928.2017.1328428 · Cited by 24
Lu, H., Ma, Y., Wang, M., Shen, J., Wu, H., Li, J., Gao, N., Gu, Y., Zhang, X., Zhang, G., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02771-w · Cited by 22
Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy
Song, Y., Liu, Y., Teo, H. Y., & Liu, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914839 · Cited by 30
“After the recognition of antigens or other stress-induced molecules expressed on tumor cells by TCR or NKR, gdT cells can mediate the direct tumor lysis by producing granzyme B, perforin, TNF-a and IFN-g (Figure 2: top right) (39, 40).”
BackgroundIL-21-mediated expansion of Vγ9Vδ2 T cells is limited by the Tim-3 pathway
Wu, K., Zhao, H., Xiu, Y., Li, Z., Zhao, J., Xie, S., Zeng, H., Zhang, H., Yu, L., & Xu, B. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.01.027 · Cited by 22
Functional and metabolic dichotomy of murine γδ T cell subsets in cancer immunity
Lopes, N., & Silva‐Santos, B. (2020) · European Journal of Immunology · doi:10.1002/eji.201948402 · Cited by 23
Self-citationLeveraging biomaterials for enhancing T cell immunotherapy
Liao, Z., Zhang, W., Zheng, H., Wang, Y., Yu, J., Li, H., & Gu, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.023 · Cited by 23
NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy
Cazzetta, V., Depierreux, D., Colucci, F., Mikulak, J., & Mavilio, D. (2023) · Cancers · doi:10.3390/cancers15041264 · Cited by 21
Jiang, J., Qu, H., Zhan, X., Liu, D., Liang, T., Chen, L., Huang, S., Sun, X., Chen, J., Chen, T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28739-1 · Cited by 22
“Gamma delta (γδ) T cells are recognized as protective cells in cancer, primarily through the production of potent cytotoxicity and interferon-γ 28 .”
BackgroundXie, B., Zhang, Y., Han, M., Wang, M., Yu, Y., Chen, X., Wu, Y., Hashimoto, K., Yuan, S., Shang, Y., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231167946 · Cited by 22
Wang, Y., Ji, N., Zhang, Y., Chu, J., Pan, C., Zhang, P., Ma, W., Zhang, X., Xi, J., Chen, M., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04514-8 · Cited by 21
Breast Cancer Immune Landscape: Interplay Between Systemic and Local Immunity
Gerashchenko, T. S., Frolova, A. A., Patysheva, M. R., Fedorov, A. A., Stakheyeva, M. N., Denisov, E. V., & Чердынцева, Н. В. (2024) · Advanced Biology · doi:10.1002/adbi.202400140 · Cited by 26
Fiala, G. J., Schaffer, A.-M., Merches, K., Morath, A., Swann, J. B., Herr, L. A., Hils, M., Esser, C., Minguet, S., & Schamel, W. W. A. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1701521 · Cited by 23
Zhao, Q., Bi, Y., Sun, H., & Xiao, M. (2021) · Disease Markers · doi:10.1155/2021/5526885 · Cited by 24
“Immune interferon (IFN), also known as IFN-γ, is an potent anticancer cytokine secreted from CTLs, NK cells, NKT cells, and γδ T cells [7, 8].”
BackgroundMetabolic Changes in Tumor Microenvironment: How Could They Affect γδ T Cells Functions?
Corsale, A. M., Simone, M. D., Presti, E. L., Picone, C., Dieli, F., & Meraviglia, S. (2021) · Cells · doi:10.3390/cells10112896 · Cited by 23
“A growing amount of evidence supports the idea that γδ T cells are involved in immune responses in the tumor microenvironment [21], although their role is still unclear, given that in different tumors they seem to correlate with positive [22] or negative [23,24] prognostic factors, or even do not correlate at all with…”
BackgroundPi, J., Zhang, Z., Yang, E., Chen, L., Zeng, L., Chen, Y., Wang, R., Huang, D., Fan, S., Lin, W., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01234-3 · Cited by 21
Suzuki, I., Kawakami, N., & Shimizu, H. (1997) · PubMed · Cited by 21
Effector Vγ9Vδ2 T cell response to congenital Toxoplasma gondii infection
Ma, L., Papadopoulou, M., Taton, M., Genco, F., Marchant, A., Meroni, V., & Vermijlen, D. (2021) · JCI Insight · doi:10.1172/jci.insight.138066 · Cited by 20
Wang, J., Peng, Z., Guo, J. R., Wang, Y., Wang, S., Jiang, H., Wang, M., Xie, Y., Li, X., Hu, M., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0088 · Cited by 20
Evolution of T cells in the cancer-resistant naked mole-rat
Lin, T., Rubinstein, N. D., Fong, N. L., Smith, M., Craft, W., Martin-McNulty, B., Perry, R., Delaney, M. A., Roy, M. A., & Buffenstein, R. (2024) · Nature Communications · doi:10.1038/s41467-024-47264-x · Cited by 25
Xiao, Z., Wang, S., Luo, L., Lv, W., Feng, P., Sun, Y., Yang, Q., He, J., Cao, G., Yin, Z., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01163-9 · Cited by 22
Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies
Tsiverioti, C. A., Gottschlich, A., Trefny, M. P., Theurich, S., Anders, H., Kroiß, M., & Kobold, S. (2024) · Biological Chemistry · doi:10.1515/hsz-2023-0317 · Cited by 23
Of vessels and cells: the spatial organization of the epididymal immune system
Guiton, R., Voisin, A., Henry-Berger, J., Saez, F., & Drevet, J. R. (2019) · Andrology · doi:10.1111/andr.12637 · Cited by 20
Alsalman, A., Al-Mterin, M. A., Murshed, K., Alloush, F., Al‐Shouli, S. T., Toor, S. M., & Elkord, E. (2022) · Cancers · doi:10.3390/cancers14133194 · Cited by 22
Adoptive Cell Therapy for T-Cell Malignancies
Fang, K., Lee, J. B., & Li, Z. (2022) · Cancers · doi:10.3390/cancers15010094 · Cited by 23
Lin, M., Sun, X. K., & Lv, L. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.04.007 · Cited by 22
Réboursière, E., Gac, A., Garnier, A., Salaün, V., Reman, O., Pham, A.-D., Cabrera, Q., Khoy, K., Vilque, J., Fruchart, C., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1321751 · Cited by 19
Lin, Y.-H., Yang, M.-C., Tseng, S.-H., Jiang, R. T., Yang, A. D., Farmer, E. A., Peng, S., Henkle, T. R., Chang, Y., Hung, C., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0358 · Cited by 20
Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
Yu, T., Yu, S.-K., Xiang, Y., Lu, K., & Sun, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.936496 · Cited by 20
“Spatiotemporal heterogeneity Resident in tissues (144) 20%–50% of the tissue-resident lymphoid compartment (145) Dominate during fetal development and childhood (146) Resident in circulating peripheral blood 2%–5% of circulating CD3+ lymphocytes (147) Dominate during adulthood Cytotoxicity Higher than d2+ T cells (144…”
BackgroundInfluentialIncorvaia, L., Rinaldi, G., Badalamenti, G., Cucinella, A., Brando, C., Madonia, G., Fiorino, A., Pipitone, A., Perez, A., Pomi, F. L., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231151845 · Cited by 19
Li, L., Tan, H., Zhou, J., & Hu, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-39935-4 · Cited by 21
“Similarly, the proportion of immune cell infiltration in low-risk group of T cells CD4 memory resting is higher than that in high-risk group in colorectal cancer 59 . γδ T cells have a recognized protective role in cancer, mainly based on their strong cytotoxicity and interferon-γ Generation of 60 .”
BackgroundMa, Z., Zhou, Z., Zhuang, H., Li, Z., Ma, Z., Huang, B., Liu, C., Gong, Y., Zou, Y., Zheng, Z., et al. (2021) · Disease Markers · doi:10.1155/2021/6682697 · Cited by 23
“Gamma Delta T cell has been considered to play protective roles in tumorigenesis, largely on the basis of their cytotoxicity and interferon-γ production, which inhibits tumor progression [35].”
BackgroundTCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
Strobel, S. B., Machiraju, D., & Hassel, J. C. (2022) · Cancers · doi:10.3390/cancers14051215 · Cited by 18
“However, several challenges need to be addressed to move forward with γδ T-cell-based TCR therapy, primarily owing to the difficulty of scaling them to therapeutic numbers ex vivo and their limited presence in the peripheral blood [50].”
BackgroundXiong, Y., Xiong, Z., Cao, H., Li, C., Wanggou, S., & Li, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1116-3 · Cited by 26
Metadata
- Authors
- Silva-Santos, B., Serre, K., & Norell, H.
- Affiliations
- University of Lisbon (PT)
- Corresponding author
- Serre, Karine
- Venue
- Nature reviews. Immunology
- Published
- 2015-10-09
- Volume
- 15
- Issue
- 11
- Pages
- 683-691
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2183777144
- Cited by
- 565
- References
- 95
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 39 · 2023: 60 · 2022: 72 · 2021: 59 · 2020: 63 · 2019: 54 · 2018: 55 · 2017: 56 · 2016: 33
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- γδ T cells, cancer immunotherapy, tumour immunity, cytotoxicity, interferon-gamma, IL-17, T cell regulation
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Humans, Neoplasms, T-Lymphocytes, Receptors, Antigen, T-Cell, gamma-delta, Interleukin-17, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.